Case Report: A Case Report of a Histological Transformation of ALK-Rearranged Adenocarcinoma With High Expression of PD-L1 to Squamous Cell Carcinoma After Treatment With Alectinib

We report an anaplastic lymphoma kinase (ALK)-positive patient shows a poor response to the ALK inhibitor alectinib due to the high expression of programmed death-ligand 1 (PD-L1). After treatment with alectinib, the pathological form changed from adenocarcinoma into squamous cell carcinoma without...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yan, Qin, Yaping, Xu, Hongen, Yao, Qihui, Gao, Yalan, Feng, Yushu, Ren, Jingli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Society Journal Archive
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262189/
https://www.ncbi.nlm.nih.gov/pubmed/34257603
http://dx.doi.org/10.3389/pore.2021.637745
_version_ 1783719141511790592
author Zhang, Yan
Qin, Yaping
Xu, Hongen
Yao, Qihui
Gao, Yalan
Feng, Yushu
Ren, Jingli
author_facet Zhang, Yan
Qin, Yaping
Xu, Hongen
Yao, Qihui
Gao, Yalan
Feng, Yushu
Ren, Jingli
author_sort Zhang, Yan
collection PubMed
description We report an anaplastic lymphoma kinase (ALK)-positive patient shows a poor response to the ALK inhibitor alectinib due to the high expression of programmed death-ligand 1 (PD-L1). After treatment with alectinib, the pathological form changed from adenocarcinoma into squamous cell carcinoma without novel genetic changes. This case may reveal a direct relationship between ALK mutation and a high level of PD-L1 expression.
format Online
Article
Text
id pubmed-8262189
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82621892021-07-12 Case Report: A Case Report of a Histological Transformation of ALK-Rearranged Adenocarcinoma With High Expression of PD-L1 to Squamous Cell Carcinoma After Treatment With Alectinib Zhang, Yan Qin, Yaping Xu, Hongen Yao, Qihui Gao, Yalan Feng, Yushu Ren, Jingli Pathol Oncol Res Society Journal Archive We report an anaplastic lymphoma kinase (ALK)-positive patient shows a poor response to the ALK inhibitor alectinib due to the high expression of programmed death-ligand 1 (PD-L1). After treatment with alectinib, the pathological form changed from adenocarcinoma into squamous cell carcinoma without novel genetic changes. This case may reveal a direct relationship between ALK mutation and a high level of PD-L1 expression. Frontiers Media S.A. 2021-04-01 /pmc/articles/PMC8262189/ /pubmed/34257603 http://dx.doi.org/10.3389/pore.2021.637745 Text en Copyright © 2021 Zhang, Qin, Xu, Yao, Gao, Feng and Ren. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Society Journal Archive
Zhang, Yan
Qin, Yaping
Xu, Hongen
Yao, Qihui
Gao, Yalan
Feng, Yushu
Ren, Jingli
Case Report: A Case Report of a Histological Transformation of ALK-Rearranged Adenocarcinoma With High Expression of PD-L1 to Squamous Cell Carcinoma After Treatment With Alectinib
title Case Report: A Case Report of a Histological Transformation of ALK-Rearranged Adenocarcinoma With High Expression of PD-L1 to Squamous Cell Carcinoma After Treatment With Alectinib
title_full Case Report: A Case Report of a Histological Transformation of ALK-Rearranged Adenocarcinoma With High Expression of PD-L1 to Squamous Cell Carcinoma After Treatment With Alectinib
title_fullStr Case Report: A Case Report of a Histological Transformation of ALK-Rearranged Adenocarcinoma With High Expression of PD-L1 to Squamous Cell Carcinoma After Treatment With Alectinib
title_full_unstemmed Case Report: A Case Report of a Histological Transformation of ALK-Rearranged Adenocarcinoma With High Expression of PD-L1 to Squamous Cell Carcinoma After Treatment With Alectinib
title_short Case Report: A Case Report of a Histological Transformation of ALK-Rearranged Adenocarcinoma With High Expression of PD-L1 to Squamous Cell Carcinoma After Treatment With Alectinib
title_sort case report: a case report of a histological transformation of alk-rearranged adenocarcinoma with high expression of pd-l1 to squamous cell carcinoma after treatment with alectinib
topic Society Journal Archive
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262189/
https://www.ncbi.nlm.nih.gov/pubmed/34257603
http://dx.doi.org/10.3389/pore.2021.637745
work_keys_str_mv AT zhangyan casereportacasereportofahistologicaltransformationofalkrearrangedadenocarcinomawithhighexpressionofpdl1tosquamouscellcarcinomaaftertreatmentwithalectinib
AT qinyaping casereportacasereportofahistologicaltransformationofalkrearrangedadenocarcinomawithhighexpressionofpdl1tosquamouscellcarcinomaaftertreatmentwithalectinib
AT xuhongen casereportacasereportofahistologicaltransformationofalkrearrangedadenocarcinomawithhighexpressionofpdl1tosquamouscellcarcinomaaftertreatmentwithalectinib
AT yaoqihui casereportacasereportofahistologicaltransformationofalkrearrangedadenocarcinomawithhighexpressionofpdl1tosquamouscellcarcinomaaftertreatmentwithalectinib
AT gaoyalan casereportacasereportofahistologicaltransformationofalkrearrangedadenocarcinomawithhighexpressionofpdl1tosquamouscellcarcinomaaftertreatmentwithalectinib
AT fengyushu casereportacasereportofahistologicaltransformationofalkrearrangedadenocarcinomawithhighexpressionofpdl1tosquamouscellcarcinomaaftertreatmentwithalectinib
AT renjingli casereportacasereportofahistologicaltransformationofalkrearrangedadenocarcinomawithhighexpressionofpdl1tosquamouscellcarcinomaaftertreatmentwithalectinib

Ejemplares similares